Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

Published
29 May 2014
From
NATAP
WHA Adopts Resolution On Hepatitis; Member States Concerned Over High Prices

The resolution urges member states “to develop multisectoral national strategies for preventing, diagnosing, and treating viral hepatitis.” The resolution also asks states to consider using the flexibilities endorsed in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to promote access to specific pharmaceutical products.

Published
23 May 2014
From
Intellectual Property Watch
Today new hepatitis resolution is passed at world health assembly; challenges World Health Organization and member states to act

Today, four years after introducing its first viral hepatitis resolution, the World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—passed the Hepatitis Resolution, which commits the WHO and United Nations (UN) member states to urgent action to address the global hepatitis pandemic, including that of hepatitis C virus (HCV).

Published
23 May 2014
From
Treatment Action Group
Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C

In 2010, the 63rd World Health assembly (WHA) adopted the first resolution on viral hepatitis; a new resolution will be presented at this assembly. We, people living with HCV, HIV/AIDS, people who use drugs, and our advocates, urge United Nations (UN) Member States to act with urgency to end the hepatitis C epidemic; it is possible!

Published
21 May 2014
From
Treatment Action Group
US health insurers say Gilead hepatitis C drug too costly

The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.

Published
21 May 2014
From
Reuters
OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe

Published
16 May 2014
From
Reuters
To curb hepatitis C, test and treat inmates

The nation's oversized prison population provides an opportunity to battle the US hepatitis C epidemic because inmates have a high prevalence of infection and are readily reachable for testing and treatment, argue authors of a new article in the New England Journal of Medicine. One in six inmates is infected and one in three infected Americans ends up locked up for at least a little time in their lives.

Published
15 May 2014
From
Eurekalert Inf Dis
Even moderate drinking increases risk of advanced liver fibrosis for people with HIV and HCV co-infection

Even moderate alcohol consumption is associated with an increased risk of advanced liver fibrosis for people living with HIV and hepatitis C virus (HCV) co-infection, investigators from the

Published
12 May 2014
By
Michael Carter
AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date. European Medicines Agency has granted AbbVie's request for accelerated assessment.

Published
08 May 2014
From
AbbVie press release
Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C

Published
08 May 2014
By
Liz Highleyman

Filter by country